Mr J. Van Roey, Tibotec
Mr J. Van Roey, Tibotec
Mr J. Van Roey, Tibotec
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Percentage of mice relapsing after treatment of Drug<br />
Susceptible -TB<br />
Microbiology data in mice and patients<br />
Percentage of mice with positive lung cultures<br />
90<br />
80<br />
70<br />
60<br />
50<br />
40<br />
30<br />
20<br />
10<br />
0<br />
2RHZ/4RH<br />
17<br />
84<br />
2RMZ/RM<br />
42<br />
56<br />
28<br />
2JRZ/JR<br />
13<br />
72<br />
68 67<br />
2JHZ/JH<br />
29<br />
35<br />
2JRHZ/JRH<br />
6<br />
2mo<br />
3mo<br />
4mo<br />
6mo<br />
Log CFU in lungs<br />
8<br />
7<br />
6<br />
5<br />
4<br />
3<br />
2<br />
1<br />
0<br />
Efficacy in Mice<br />
0 2 4 6 8<br />
weeks<br />
Lounis et al. AAC. 2006<br />
AEtMZ<br />
AEtMZ+ TMC<br />
Log CFU in sputum<br />
8<br />
7<br />
6<br />
5<br />
4<br />
3<br />
2<br />
1<br />
0<br />
Efficacy in MDR TB patients<br />
KEtOZ+TMC<br />
KEtOZ<br />
0 2 4 6 8<br />
Weeks<br />
Diacon et al. NEJM. 2009<br />
45<br />
Veziris et al. ICAAC, 2007<br />
A= amikacin Et=ethionamide M=moxifloxacin Z=pyrazinamide K= kanamycin O=ofloxacin<br />
46<br />
New MDR-TB drugs – Jens <strong>Van</strong> <strong>Roey</strong>
Change language